D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
Janaki Amin,Mark A. Boyd,Nagalingeswaran Kumarasamy,Cecilia L. Moore,M. H. Losso,Chidi Nwizu,Lerato Mohapi,Stephen J. Kerr,Annette H. Sohn,Hedy Teppler,Boris Renjifo,Jean-Michel Molina,Sean Emery,David A. Cooper +13 more
TL;DR: The results support the use of a combination LPV/r and RAL regimen as an option following failure of 1st line NNRTI + 2N(t)RTIs.
Journal ArticleDOI
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study
Alan Winston,Rebekah Puls,Stephen J. Kerr,Chris Duncombe,Patrick C.K. Li,John Gill,Simon D. Taylor-Robinson,Sean Emery,David A. Cooper +8 more
TL;DR: Improvements in neurocognitive function have been associated with commencing antiretroviral therapy in HIV‐infected subjects, but the dynamics of such improvements are poorly understood.
Journal ArticleDOI
The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis
Alan Winston,Alan Winston,John McAllister,Janaki Amin,David A. Cooper,David A. Cooper,Andrew Carr +6 more
TL;DR: The aim of this study was to compare side effects and numbers of individuals completing NPEP before and after the change in standard NPEP treatment to 28 days of TDF‐3TC‐d4T.
Journal ArticleDOI
Persistent Survival of Prevalent Clonotypes within an Immunodominant HIV Gag-Specific CD8+ T Cell Response
David van Bockel,David Price,David Price,Mee Ling Munier,Vanessa Venturi,Tedi E. Asher,Kristin Ladell,Hui Yee Greenaway,John Zaunders,Daniel C. Douek,David A. Cooper,Miles P. Davenport,Anthony D. Kelleher +12 more
TL;DR: Examination of Ag-specific CD8+ TCR repertoires longitudinally in a cohort of HLA-B*2705+ long-term nonprogressors with chronic HIV-1 infection suggests an antiapoptotic phenotype and the ability to cross-recognize variant epitopes contribute to clonotype longevity and selection within the peripheral memory T cell pool in the presence of persistent infection with a genetically unstable virus.
Journal ArticleDOI
Frequent transmission of cytotoxic-T-lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese population.
Tae Furutsuki,Noriaki Hosoya,Ai Kawana-Tachikawa,Mariko Tomizawa,Takashi Odawara,Mieko Goto,Yoshihiro Kitamura,Tetsuya Nakamura,Anthony D. Kelleher,David A. Cooper,Aikichi Iwamoto +10 more
TL;DR: HIV-1 with Nef138-10(2F) appears to be a cytotoxic-T-lymphocyte escape mutant and has been transmitted frequently by sexual contact among the highly A24-positive Japanese population.